Search

Polyethylene glycol

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a rati...

Ipratropium

[A176939] It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. … ] was approved in 1996.

Florfenicol

Florfenicol is a fluorinated synthetic analog of thiamphenicol.

Rociverine

Brivaracetam

It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].

Tipiracil

It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF

Azelastine

[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996. … Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic

Trifluridine

It displays effective antiviral activity against Herpes simplex virus type 1 and 2 [A35271]. … The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal

Mannitol

Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a … On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for

Tamsulosin

[A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238] … [Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.